New Alzheimer’s drugs: hope and inequity

Harvard Health

While the new Alzheimer’s drugs bring hope by potentially slowing down the debilitating disease’s progression, it also highlights significant disparities. The medications have not been extensively tested in Black people with Alzheimer’s, with Black individuals accounting for only 2-4% of the participants in clinical trials in both the U.S. and internationally. This health disparity points to an urgent need for more inclusive research practices in the development of these drugs, aiming to ensure that every patient regardless of demographics and socioeconomic backgrounds can share in the advancements against Alzheimer’s disease.

Source

New Alzheimer’s Drugs Bring Hope. but Not Equally for All Patients., www.washingtonpost.com/health/2024/01/29/alzheimers-new-drugs-black-patients-leqembi/. Accessed 1 Feb. 2024.